Perspective Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
SEATTLE, Jan. 02, 2024 (GLOBE NEWSWIRE) — Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that Thijs […]
BetterLife Announces Closing of Convertible Debentures For Further Development of BETR-001
VANCOUVER, British Columbia, Jan. 02, 2024 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF […]
Hydrofarm Holdings Group to Participate in the 2024 ICR Conference
SHOEMAKERSVILLE, Pa., Jan. 02, 2024 (GLOBE NEWSWIRE) — Hydrofarm Holdings Group, Inc. (“Hydrofarm” or the “Company”) (Nasdaq: HYFM), a leading […]
INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune™ in Patients with Metastatic Castration-Resistant Prostate Cancer
Boca Raton, Florida, Jan. 02, 2024 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused […]
CymaBay Therapeutics to Present at the 42nd Annual JP Morgan Healthcare Conference 2024
NEWARK, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies […]
EDAP Appoints Ken Mobeck, Global Chief Financial Officer, and Francois Dietsch, Global Chief Accounting Officer
LYON, France, January 2, 2024 – EDAP TMS SA (Nasdaq: EDAP), (“EDAP”), the global leader in robotic energy-based therapies, […]
H World Group Limited Announces the Change of Officers
SHANGHAI, China, Jan. 02, 2024 (GLOBE NEWSWIRE) — H World Group Limited (NASDAQ: HTHT and HKEX: 1179) (“H World” or […]
Kadant Completes Acquisition of Key Knife, Inc.
WESTFORD, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) — Kadant Inc. (NYSE: KAI) has completed its previously announced acquisition of Key […]
Streamline Health® Expands Agreement With Existing eValuator™ Client to Add RevID™
6 facility New York health system becomes first client leveraging both eValuator and RevID to improve revenue integrity pre-bill Atlanta, […]
XOMA Announces Stock Repurchase Program of up to $50 Million
EMERYVILLE, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) — XOMA Corporation (Nasdaq: XOMA), the biotech royalty aggregator, today announced its Board […]
